Guggenheim Reaffirms “Buy” Rating for Arcutis Biotherapeutics (NASDAQ:ARQT)
Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at Guggenheim in a research note issued on Monday,Benzinga reports. Several other research analysts have also recently weighed in on ARQT. HC Wainwright reiterated a “buy” rating and set a $19.00 price target on shares of Arcutis Biotherapeutics in […]
Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at Guggenheim in a research note issued on Monday,Benzinga reports. Several other research analysts have also recently weighed in on ARQT. HC Wainwright reiterated a “buy” rating and set a $19.00 price target on shares of Arcutis Biotherapeutics in […]
